Riskpilot← Back to searchSign inGet full accessNiklovir AB
ABDissolvedOrg 5591520225Medical specialists activities · NACE 8622Est. 20181 employees
Revenue 2023
SEK 505K
-27% vs 2022
EBITDA margin
36.9%
-57% vs 2022
Equity ratio
27.0%
Financial strength
Net profit 2023
SEK 66K
-76% vs 2022
| Revenue | SEK 505K | -27% |
| EBITDA | SEK 186K | -57% |
| Net profit | SEK 66K | -76% |
| Total assets | SEK 502K | +4% |
| Equity | SEK 135K | -59% |
| Employees | 1 | — |
Legal name
Niklovir AB
Org number
5591520225
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
12 mars 2018
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanterna
Company purpose
Aktiebolaget ska hyra ut sig själv som läkare med behandlings och konsultuppdrag samt medicinsk forskning, utveckling och undervisning.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue | 367 | 716 | 389 | 687 | 505 |
| Staff expenses | — | — | — | −80 | −38 |
| EBITDA | 173 | 437 | 217 | 432 | 186 |
| Depreciation & amort. | −29 | −45 | −67 | −83 | −101 |
| EBIT | 144 | 392 | 150 | 350 | 85 |
| Net financials | — | — | — | −0 | 1 |
| Profit before tax | 106 | 479 | 150 | 350 | 86 |
| Tax | −25 | −105 | −32 | −74 | −20 |
| Net profit | 81 | 374 | 118 | 276 | 66 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Total assets | 363 | 921 | 354 | 480 | 502 |
| Equity | 235 | 608 | 187 | 326 | 135 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 42 | 312 | 168 | 154 | 366 |
| Total debt | 42 | 312 | 168 | 154 | 366 |
EBITDA margin
36.9%
This company
15.8%
Market median
+134% vs market
20192023
Equity ratio
27.0%
This company
38.2%
Market median
-29% vs market
20192023
Return on equity
48.8%
This company
18.4%
Market median
+165% vs market
20192023
Net profit margin
13.1%
This company
8.1%
Market median
+62% vs market
20192023
Asset turnover
1.01×
This company
1.12×
Market median
+10% vs market
20192023
Debt / equity
2.71×
This company
0.62×
Market median
-337% vs market
20192023
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
BS Chief Executive Officer | Chief Executive Officer | 2022 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Deputy Board Member | 2025 | |
| Deputy Board Member | 2025 | |
| Board of Directors | 2025 | |
| Deputy Board Member | 2025 | |
| Former (1) | ||
| Deputy Board Member | 2022 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Niklovir AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bo Staffan Niklasson | Chief Executive Officer | 0 companies |
| Lena Birgitta Killgren Jonsson | Deputy Board Member | 0 companies |
| Inger Margareta Dahle | Deputy Board Member | 0 companies |
| Bengt Junior Niklas Nygårds | Board of Directors | 0 companies |
| Ulrika Margareta Ahlholm | Deputy Board Member | 0 companies |
| Malin Christine Niklasson | Deputy Board Member | 0 companies |